Research never stops

Yale/Open innovation

In January 2013, Evotec and Yale University entered into a strategic partnership.

Under the agreement, Evotec and Yale intend to leverage first rate science performed at Yale University together with Evotec‘s drug discovery infrastructure and expertise into highly innovative discovery approaches in diseases of high unmet medical need. Initially, Evotec and Yale have defined a wide range of scientific fields including metabolic diseases, CNS, immunological diseases and cancer where they will jointly assess and potentially pursue novel assays, screens and models but in particular exploratory drug targets and compounds. The intention is to seamlessly integrate Evotec’s drug discovery infrastructure with highly innovative biology at Yale to mature individual projects to a stage where they can be commercialised.

In December 2013, Evotec entered into a first research collaboration as part of this open innovation alliance (TargetDBR).